Syntara Expands Scar Treatment Study
Syntara will add 10 participants to the initial 20-patient Phase 1b study cohort of its topical anti-fibrotic drug candidate SNT-9465, developed to improve hypertrophic sternotomy scars.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.